[Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy].
We report a clinical case of a patient with NSCLC who experienced an atrial fibrillation during paclitaxel infusion. Before chemotherapy, his cardiological function was normal. No cardiovascular and/or thyroid associated disease were previously reported. The patient did not receive any drugs with pro-arrhythmic effects. Incidence of cardiovascular toxicity in patients treated with paclitaxel is low, and does not justify strict cardiological monitoring otherwise deserved to patients with preexistent risk factors.
Moscetti
L
L
Dipartimento di Medicina Sperimentale, Università La Sapienza, Italia.
Ramponi
S
S
Maccaglia
C
C
Villanti
P
P
Cortesi
E
E
D001281:Atrial Fibrillation / Q000139:chemically induced*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*
D017239:Paclitaxel